

Institute of Pharmacology¹, School of Basic Medical Science, Lanzhou University, Gansu Province Key Laboratory of Preclinical Study for New Drugs, Lanzhou; Gansu Tumor Hospital²; School of Life Science³, Lanzhou University, Lanzhou, China

Therapeutic effects of a recombinant mutant of the human ciliary neurotrophic factor in a mouse model of metabolic syndrome

MING-XIA CUI¹, JUN-FENG JIANG², RONG-LIANG ZHENG³, RUI-LIAN LI¹, LEI WANG¹, WEN-GUANG LI¹, MING-TANG GAO¹, LI-NING YANG¹, JIN-YAN DOU¹, YONG-JIE WU¹

Received July 22, 2009, accepted October 9, 2009

Yong-Jie Wu, Institute of Pharmacology, School of Basic Medical Science, Lanzhou University, Gansu Province Key Laboratory of Preclinical Study for New Drug, No.199 Donggang Xi Road, Lanzhou 730000, China
wuyj@lzu.edu.cn

Pharmazie 65: 279–283 (2010)

doi: 10.1691/ph.2010.9713

Metabolic syndrome (MS) is highly prevalent in developed countries and becoming a serious worldwide public health issue. In this study, we established a MS model by feeding male C57BL/6J mice with a high-fat diet (10%) for 18.5 weeks, studied the therapeutic effects of a recombinant mutant of the human ciliary neurotrophic factor (rhmcNTF) 0.1 (C-0.1) or 0.3 (C-0.3) mg·kg⁻¹ per day subcutaneously or pair feeding (PF, which mice were restricted to the same amount of food as eaten by C-0.3 treated mice) in MS mice. After 10 days treatment, rhmcNTF reduced obesity related indices, ameliorated glucose and lipid metabolism abnormality, and enhanced insulin sensitivity. In addition, liver function and antioxidant ability of MS mice were improved by rhmcNTF. Pair feeding revealed the same effects as C-0.3 on obesity related indices and insulin sensitivity, but aggravated hepatic steatosis and hepatic function. The results suggest that rhmcNTF could serve as an effective therapeutic agent for MS and related diseases.

1. Introduction

Metabolic syndrome (MS) is defined as a cluster of abnormalities including abdominal obesity, insulin resistance, type 2 diabetes mellitus, dyslipidaemia, hypertension, non-alcoholic fatty liver diseases, and/or cardio-cerebrovascular diseases, etc (Unger 2002; Dandona et al. 2005). It is highly prevalent in developed countries (Meigs 2002) and becoming a serious worldwide public health issue (Haffner and Taegtmeier 2003). Among these disorders, abdominal obesity and ectopic fat deposition are the central feature and main reason for MS (Lebovitz 2003; Turkoglu et al. 2003; Grundy 2004).

The ciliary neurotrophic factor (CNTF) was first used as a trophic factor for amyotrophic lateral sclerosis to attenuate disease progression (ALS CNTF Treatment Study Group 1996). But patients treated with CNTF underwent marked weight loss and nausea. Since then, CNTF was studied as an anti-obesity agent at a lower dose. Previous reports indicated that CNTF or CNTF analogs decreased body weight and ameliorated the metabolic abnormalities induced by obesity in *ob/ob* mice (Gloaguen et al. 1997; Lambert et al. 2001), *db/db* mice (Gloaguen et al. 1997; Sleeman et al. 2003), diet-induced AKR/J obese mice (Gloaguen et al. 1997; Lambert et al. 2001) and obese diabetic KK/Ay mice (Liu et al. 2007a,b). But in a phase III trial, the efficacy of recombinant human CNTF (Axokine, Regeneron Pharmaceuticals, Tarrytown, NY) for obesity treatment was limited by the development of antibodies in two thirds of the subjects (Korner and Aronne 2004).

To enhance biological activity and decrease immunogenicity of CNTF, a novel mutant of recombinant human CNTF (rhmcNTF) was obtained, which is a truncated form of CNTF with the last 14 C-terminal amino acids removed and glycine

at position 185 and isoleucine at position 186 are replaced by lysine and methionine, respectively. In this study, we established MS models by feeding C57BL/6J mice with high-fat diet (HFD) for 18.5 weeks and studied the therapeutic effects of rhmcNTF.

2. Investigations and results

2.1. Characteristics of MS model

After 18.5-week feeding with HFD and 10 days injection with saline plus feeding with HFD, MS mice were abdominal obesity, hypercholesterolemia, hyperglycemia, hyperinsulinemia, and insulin resistance (Table). In addition, mice had significantly increased liver weight and hepatic steatosis (Figs. 1 and 2). These symptoms were similar to those in humans. No animal died prior to the time of examination from any groups.

2.2. Effects of rhmcNTF on obesity related indices

The treatment of rhmcNTF decreased body weight in dose-dependent manner in MS mice (Fig. 3). After 10 days treatment, rhmcNTF 0.3 mg kg⁻¹ per day (C-0.3) produced greater weight loss than pair-feeding (PF, which restricted food intake to same amount as eaten by the C-0.3 treated mice) (Table). The wet weight of visceral fat and fat coefficient of C-0.3 and pair feeding mice were both reduced significantly (Table).

2.3. Effects of rhmcNTF on serum lipid levels

The cholesterol in HFD led to decrease in serum triglyceride (TG) level. This result is consistent with that reported by Savransky et al. (2007). The serum level of TG was significantly decreased in C-0.1, C-0.3 and PF group by 38.5%,

Table: Effects of rhmCNTF or pair-feeding on obesity related indices, serum levels, and insulin sensitivity in metabolic syndrome (MS) mice

	Normal <i>n</i> = 10	Vehicle <i>n</i> = 14	PF <i>n</i> = 14	C-0.1 <i>n</i> = 14	C-0.3 <i>n</i> = 14
Body weight (g)	27.5 ± 1.9	28.6 ± 1.6	25.6 ± 2.1**	26.3 ± 1.2**	23.5 ± 1.8**‡
Wet weight of visceral fat (g)	0.78 ± 0.07*	1.04 ± 0.32	0.71 ± 0.32*	0.98 ± 0.34	0.68 ± 0.19**
Visceral fat coefficient (%)	2.84 ± 0.33*	3.77 ± 1.00	2.71 ± 1.04*	3.70 ± 1.21	2.87 ± 0.69**
Triglyceride (mmol·L ⁻¹)	1.06 ± 0.13*	0.83 ± 0.19	0.61 ± 0.12*	0.51 ± 0.16**	0.53 ± 0.15**
Total cholesterol (mmol·L ⁻¹)	2.91 ± 0.32**	3.81 ± 0.29	3.54 ± 0.12	3.58 ± 0.24	3.44 ± 0.19*
FBG (mmol·L ⁻¹)	4.49 ± 0.69**	6.03 ± 1.33	4.07 ± 1.18**	5.31 ± 1.10	4.88 ± 1.09*
FINS (μg·L ⁻¹)	0.24 ± 0.05**	0.42 ± 0.12	0.29 ± 0.09**	0.38 ± 0.10	0.32 ± 0.08*
FIRI	1.21 ± 0.39**	2.65 ± 1.29	1.21 ± 0.61**	2.02 ± 0.74	1.62 ± 0.61*

MS mice were treated for 10 days with saline (vehicle) or rhmCNTF 0.1, 0.3 mg kg⁻¹ per day subcutaneously, or were pair-fed to the food intake of C-0.3 group (PF). FBG: fasting blood glucose, FINS: fasting serum insulin level; FIRI: fasting insulin resistance index, FIRI = FBG (mmol·L⁻¹) × FINS (mIU·L⁻¹)/25. All data are mean ± S.D.

* *P* < 0.05

** *P* < 0.01 versus vehicle group

‡ *P* < 0.01 when C-0.3 group versus PF group




Fig. 1: Effect of rhmCNTF or pair-feeding on hepatic steatosis in metabolic syndrome (MS) mice. MS mice were treated for 10 days with saline (vehicle), or rhmCNTF 0.3 mg kg⁻¹ per day subcutaneously (C-0.3), or were pair-fed to the food intake of C-0.3 mice (PF). Liver sections were H&E or oil red O stained (magnification ×400)

36.1%, and 26.5%, respectively (Table). The serum level of total cholesterol (TC) was significantly decreased in the C-0.3 group by 9.7% as compared with the MS model group (*P* < 0.05). TC level decreased slightly in C-0.1 and PF groups but had no statistically significant difference as compared with MS model group (Table).

2.4. Effects of rhmCNTF on insulin sensitivity

The hyperglycemia, hyperinsulinemia, and insulin resistance in MS mice were corrected effectively in C-0.3 and PF groups, but not in the C-0.1 group (Table). Insulin sensitivity in the PF group was improved closely to that in normal group and seems superior to that of the rhmCNTF 0.3 mg kg⁻¹ treatment group (Table).

2.5. Effects of rhmCNTF on hepatic steatosis and hepatic function

The MS mice had hepatic steatosis and significantly increased liver weight (both *P* < 0.05) in conjunction with slightly elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (*P* > 0.05). The treatment of rhmCNTF showed a trend of improvement on hepatic steatosis (*P* > 0.05,

Figs. 1 and 2A) associated with a significant reduction of serum levels of ALT in both C-0.1 and C-0.3 groups (Fig. 2C) and AST in C-0.1 group (Fig. 2D). On the contrary, pair feeding had an aggravated tendency on hepatic steatosis (*P* > 0.05, Figs. 1 and 2A) associated with the significant elevation of liver free fatty acid (FFA) concentration (Fig. 2B) and serum ALT level (Fig. 2C). The difference of the hepatic steatosis degree, liver FFA content, serum levels of ALT and AST had statistical significance between C-0.3 group and PF group (Fig. 2A, B, C, D). The liver weight loss of C-0.3 group was equivalent to that in PF group (Fig. 2E).

2.6. Effects of rhmCNTF on antioxidant ability in MS mice

The MS mice had a significantly elevated liver total antioxidant capacity (T-AOC), but not a significantly changed liver malondialdehyde (MDA) level. The 10 days injection of rhmCNTF increased liver T-AOC and decreased liver MDA level significantly (Fig. 4). The effects of pair-feeding on liver T-AOC and MDA were similar to that of rhmCNTF (Fig. 4).




Fig. 2: Effect of rhmCNTF or pair-feeding on hepatic steatosis and hepatic function in metabolic syndrome (MS) mice. MS mice were treated for 10 days with saline (vehicle), or rhmCNTF 0.1, 0.3 mg kg^{-1} per day subcutaneously (C-0.1, C-0.3), or were pair-fed to the food intake of C-0.3 mice (PF). (A) The degree of steatosis was classified as absent, or present in < 30% hepatocytes (mild), 30–60% hepatocytes (moderate), or > 60% hepatocytes (severe). Animals were 10 in normal group and 14 in other groups. Chi square test was used for the ranked data statistical analysis. (B) Liver free fatty acid (FFA) content, $n = 10$ –14. (C) The level of serum alanine aminotransferase (ALT) and (D) aspartate aminotransferase (AST), $n = 5$ –6. (E) Liver weight, $n = 10$ –14. Data are mean \pm S.D. in figure B, C, D, and E. * $P < 0.05$, ** $P < 0.01$ versus vehicle group; † $P < 0.05$, ‡ $P < 0.01$ when C-0.3 group versus PF_{C-0.3} group

3. Discussion

Metabolic syndrome (MS) is characterized by abdominal obesity complicated by insulin resistance, type 2 diabetes mellitus, and dyslipidaemia, *etc.* In this study, MS mice were abdominal obesity, hypercholesterolemia, hyperglycemia, hyperinsulinemia, insulin resistance and hepatic steatosis. These symptoms are similar to those in humans. In addition, the results showed that model mice had hepatic triglyceride accumulation, but had no obviously increased aminotransferase level, hepatic FFA content and oxidative stress. The level of hepatic T-AOC even

compensatory increased. These results indicated that mice simply showed hepatic steatosis alone. The triglyceride synthesis actually helps to protect hepatocytes from lipotoxicity by buffering the accumulation of FFA (Yamaguchi et al. 2007).

The treatment with rhmCNTF reduced obesity related indices, ameliorated glucose and lipid metabolism abnormality, enhanced insulin sensitivity and hepatic antioxidant ability, and slightly improved hepatic steatosis and function. Sleeman et al. (2003) also reported that CNTF_{AX15} lowers the degree of hepatic steatosis in conjunction with improved liver function,




Fig. 3: Effect of rhmCNTF or pair-feeding on body weight in metabolic syndrome (MS) mice. MS mice were treated for 10 days with saline (vehicle) or rhmCNTF 0.1, 0.3 mg kg⁻¹ per day subcutaneously (C-0.1, C-0.3), or were pair-fed to the food intake of C-0.3 mice (PF). Body weight is shown as percentage difference from that of day 0. All data are mean \pm S.D., $n = 10-14$

liver insulin signaling, and metabolic rate in *db/db* mice. One reason for enhanced insulin sensitivity after CNTF treatment is increased glucose uptake and insulin signaling in skeletal muscle (Watt et al. 2006). RhmCNTF enhanced hepatic antioxidant ability shown in this study may be a mechanism for improvement of hepatic function.

Pair feeding, during which mice were restricted to the same amount of food as eaten by C-0.3 treated mice revealed the same effects as C-0.3 on weight loss, liver weight and visceral fat weight reduction, and improvement of insulin sensitivity, but aggravated accumulation of FFA, hepatic steatosis and liver damage. The results showed that caloric restriction reduced visceral fat mass and thus enhanced insulin sensitivity. But short-term severe caloric restriction exaggerated fat mobilization from peripheral adipocytes, which in turn increased the content of FFA in liver and led to liver function damage. This indicates that rhmCNTF has other important mechanisms not limited in food intake reduction. Administration of CNTF_{A \times 15} produced a marked improved insulin and lipid homeostasis in DIO mice without elevating corticosterone levels but food restriction increased circulating adrenal corticosteroids (Lambert et al. 2001).

4. Experimental

4.1. Protein

The genetically engineered recombinant human mutant of ciliary neurotrophic factor (rhCNTF) was manufactured by the Lanzhou Institute of Biological Products (Lanzhou, China). The purity of protein is higher than 95%.

4.2. High-fat diet

The high-fat diet (HFD) containing 10% fat (w/w), 2% cholesterol (w/w), and 0.4% sodium cholate in basic diet was obtained from Suzhou Shuangshi Laboratory Animal Feed Science Co. Ltd. (Suzhou, China).

4.3. Animals

Nine-week-old male C57BL/6J mice weighing 18–22 g were obtained from the Shanghai Laboratory Animal Center (Shanghai, China) housed under standard laboratory condition with a 12 h/12 h light-dark cycle (7:00–19:00), at a temperature of 20–22 °C, and a humidity of 40–60%. All animal procedures were conducted in compliance with the guidelines for animal care and use of Gansu Province Key Laboratory of Preclinical Study for New Drug, China.

4.4. Experimental protocol

After 7 days adaptation, mice were fed with HFD *ad libitum* for 18.5 weeks to produce the MS model, except for the mice which were fed with basic diet as normal control group. MS mice were subcutaneously injected with saline/vehicle (in model control group) or rhmCNTF 0.1 (C-0.1), 0.3 (C-0.3) mg·kg⁻¹ per day, or pair-fed (PF, where mice were restricted to the same amount of food as eaten one day before by C-0.3 mice) for 10 days. Body weight and food intake were measured daily. To facilitate measurement of food intake, mice were transferred from group housing to single housing. On day 11, 16 h after the last administration, all mice were killed for serum and tissues analysis.

4.5. Serum samples analysis

Serum samples were taken to determine fasting blood glucose (FBG) by colorimetry, fasting serum insulin (FINS) by rat/mouse insulin ELISA kit (the product of Linco Research, Inc., St. Charles, Missouri, USA), triglyceride (TG), total cholesterol (TC), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) with an automatic biochemistry analyzer. Fasting insulin resistance index (FIRI) were calculated as in equation: $FIRI = FBG (mmol \cdot L^{-1}) \times FINS (mIU \cdot L^{-1}) / 25$.

4.6. Tissues analysis

The liver and visceral fat (perirenal fat and epididymal fat pads) wet weight was measured. The liver tissue of every animal was divided into three parts. One part was fixed in 10% formalin, embedded in paraffin, sectioned and stained with haematoxylin and eosin (H&E). One part was for frozen section and stained with oil red O. The degree of hepatic steatosis was evaluated




Fig. 4: Effect of 10 days subcutaneous injection of rhmCNTF or pair-feeding on Liver total antioxidant capacity (T-AOC) and content of malondialdehyde (MDA) in metabolic syndrome (MS) mice. All data are mean \pm S.D., $n = 10-14$. * $P < 0.05$, ** $P < 0.01$ versus vehicle group

by light microscopy and graded as follows: absent (no hepatocyte is steatosis), mild (present in <30% hepatocytes), moderate (30–60% hepatocytes), or severe (>60% hepatocytes). The last part tissue was minced and homogenized in cold physiological saline on ice to determine free fatty acid (FFA) and total antioxidant capacity (T-AOC) by a colorimetric method, malondialdehyde (MDA) by thiobarbituric acid reactive substance assay. Kits were products of Jiancheng Bioengineering Institute, Nanjing, China),

4.7. Statistical analysis

The data were expressed as mean \pm S.D. Statistical comparisons between groups were carried out using ANOVA. Chi square test was used for the ranked data statistical analysis. $P < 0.05$ was considered significant.

Acknowledgements: We thank professor Lin Jiang (Lanzhou Institute of Biological Products, Lanzhou, China) for provide of rhmCNTF. This study was supported by the Natural Science Foundation of Gansu Province (No 3ZS051-A25-091) and National Natural Science Foundation of China (No 30600770).

References

- ALS CNTF Treatment Study Group (1996) A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. *Neurology* 46: 1244–1249.
- Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. *Circulation* 111: 1448–1454.
- Gloaguen I, Costa P, Demartis A, Lazzaro D, DI Marco A, Grazzini R, Paonessa G, Chen F, Rosenblum CI, Van der Ploeg LH, Cortese R, Ciliberto G, Laufer R (1997) Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. *Proc Natl Acad Sci USA* 94: 6456–6461.
- Grundy SM (2004) What is the contribution of obesity to the metabolic syndrome? *Endocrinol Metab Clin North Am* 33: 267–282.
- Haffner S, Taegtmeier H (2003) Epidemic obesity and the metabolic syndrome. *Circulation* 108: 1541–1545.
- Korner J, Aronne LJ (2004) Pharmacological approaches to weight reduction: therapeutic targets. *J Clin Endocrinol Metab* 89: 2616–2621.
- Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hajarunguru A, Corcoran TL, Murray JD, Thabet KE, Yancopoulos GD, Wiegand SJ (2001) Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. *Proc Natl Acad Sci USA* 98: 4652–4657.
- Leibovitz HE (2003) The relationship of obesity to the metabolic syndrome. *Int J Clin Pract Suppl* 134: 18–27.
- Liu QS, Gao M, Zhu SY, Li SJ, Zhang L, Wang QJ, Du GH (2007a) The novel mechanism of recombinant human ciliary neurotrophic factor on the anti-diabetes activity. *Basic Clin Pharmacol Toxicol* 101: 78–84.
- Liu QS, Wang QJ, Du GH, Zhu SY, Gao M, Zhang L, Zhu JM, Cao JF (2007b) Recombinant human ciliary neurotrophic factor reduces weight partly by regulating nuclear respiratory factor 1 and mitochondrial transcription factor A. *Eur J Pharmacol* 563: 77–82.
- Meigs JB (2002) Epidemiology of the metabolic syndrome, 2002. *Am J Manag Care* 8: S283–292.
- Savransky V, Nanayakkara A, Li J, Bevans S, Smith PL, Rodriguez A, Polotsky VY (2007) Chronic intermittent hypoxia induces atherosclerosis. *Am J Respir Crit Care Med* 175: 1290–1297.
- Sleeman MW, Garcia K, Liu R, Murray JD, Malinova L, Moncrieffe M, Yancopoulos GD, Wiegand SJ (2003) Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice. *Proc Natl Acad Sci USA* 100: 14297–14302.
- Turkoglu C, Duman BS, Gunay D, Cagatay P, Ozcan R, Buyukdevrim AS (2003) Effect of abdominal obesity on insulin resistance and the components of the metabolic syndrome: evidence supporting obesity as the central feature. *Obes Surg* 13: 699–705.
- Unger RH (2002) Lipotoxic diseases. *Annu Rev Med* 53: 319–336.
- Watt JA, Bone S, Pressler M, Cranston HJ, Paden CM (2006) Ciliary neurotrophic factor is expressed in the magnocellular neurosecretory system of the rat *in vivo*: evidence for injury and activity-induced up-regulation. *Exp Neurol* 197: 206–214.
- Watt MJ, Dzamko N, Thomas WG, Rose-John S, Ernst M, Carling D, Kemp BE, Febbraio MA, Steinberg GR (2006) CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. *Nat Med* 12: 541–548.
- Xu B, Dube MG, Kalra PS, Farmerie WG, Kaibara A, Moldawer LL, Martin D, Kalra SP (1998) Anorectic effects of the cytokine, ciliary neurotrophic factor, are mediated by hypothalamic neuropeptide Y: comparison with leptin. *Endocrinology* 139: 466–473.
- Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM (2007) Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. *Hepatology* 45: 1366–1374.